Case report: Blepharospasm in peak-dose dyskinesia may benefit from amantadine in Parkinson's disease

Overview of attention for article published in Frontiers in Neurology, September 2022

Altmetric Badge

About this Attention Score

Average Attention Score compared to outputs of the same age
Good Attention Score compared to outputs of the same age and source (66th percentile)

Mentioned by

twitter: 4 X users

Readers on

mendeley: 2 Mendeley

Summary X

So far, Altmetric has seen 4 X posts from 4 X users, with an upper bound of 11,439 followers.

New article: Case report: Blepharospasm in peak-dose dyskinesia may benefit from amantadine in Parkinson's disease https://t.co/7aR9jnVLrq #parkinsons #neurology https://t.co/3gnaS32v5Z

17 Oct 2022

Reply Repost Favourite

RT @FrontNeurol: New Research: Case report: Blepharospasm in peak-dose dyskinesia may benefit from amantadine in Parkinson's disease: Intro…

01 Oct 2022

Reply Repost Favourite

Case report: Blepharospasm in peak-dose dyskinesia may benefit from amantadine in Parkinson's disease https://t.co/hZDOccmdJm #Parkinson #neurologia

30 Sep 2022

Reply Repost Favourite

New Research: Case report: Blepharospasm in peak-dose dyskinesia may benefit from amantadine in Parkinson's disease: Introduction Blepharospasm is uncommon in Parkinson's disease, especially in the peak-dose dyskinesia https://t.co/9PoEvzp8qZ… https://t.c

30 Sep 2022

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.